Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Jacobstein

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Medgenmed : Medscape General Medicine|December 22, 2005
A 2-month-old with persistent diarrheaDouglas Jacobstein, Jonathan Markowitz, Petar Mamula
Journal of Crohn'S & Colitis|May 5, 2018
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's DiseaseBruce E Sands, Chenglong Han, Christopher Gasink, et al.
Journal of Crohn'S & Colitis|May 26, 2021
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 StudyJoel R Rosh, Dan Turner, Anne Griffiths, et al.
Gastroenterology|July 8, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's DiseaseKatherine Li, Joshua R Friedman, Daphne Chan, et al.
Gastroenterology|February 8, 2018
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, et al.
Gastroenterology|June 18, 2018
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's DiseasePaul Rutgeerts, Christopher Gasink, Daphne Chan, et al.
Journal of Crohn'S & Colitis|June 4, 2019
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's DiseaseStephen B Hanauer, William J Sandborn, Brian G Feagan, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Medgenmed : Medscape General Medicine|December 22, 2005
A 2-month-old with persistent diarrheaDouglas Jacobstein, Jonathan Markowitz, Petar Mamula
Journal of Crohn'S & Colitis|May 5, 2018
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's DiseaseBruce E Sands, Chenglong Han, Christopher Gasink, et al.
Journal of Crohn'S & Colitis|May 26, 2021
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 StudyJoel R Rosh, Dan Turner, Anne Griffiths, et al.
Gastroenterology|July 8, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's DiseaseKatherine Li, Joshua R Friedman, Daphne Chan, et al.
Gastroenterology|February 8, 2018
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, et al.
Gastroenterology|June 18, 2018
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's DiseasePaul Rutgeerts, Christopher Gasink, Daphne Chan, et al.
Journal of Crohn'S & Colitis|June 4, 2019
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's DiseaseStephen B Hanauer, William J Sandborn, Brian G Feagan, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Pageof 1